Medscape

Finally, some good news about CCR5 antagonists

The past 6 months have been difficult for the developers of CCR5 antagonists. First, GlaxoSmithKline halted Phase III studies of aplaviroc because of serious hepatotoxicity (ACC Sep 28 2005), and then ...
The Scientist

A Novel CCR5 Antagonist for Multiple Therapeutic Applications

Jacob Lalezari of CytoDyn shares insights about CCR5-targeting therapy for cancer, including triple negative breast cancer and colorectal cancer.
Medscape

Maraviroc: A Coreceptor CCR5 Antagonist for Management of HIV Infection

Am J Health Syst Pharm. 2009;66(8):715-726. Mechanism of action of maraviroc. Before fusion of the HIV viral envelope and host cell membrane can occur, an HIV glycoprotein complex consisting of ...
Seeking Alpha

CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors

VANCOUVER, Washington, May 13, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...
Seeking Alpha

CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab

VANCOUVER, Washington, July 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...
Morningstar

CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories

VANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential ...
Business Wire

Aphios Awarded NIH SBIR Grant For Development of Anti-CCR5 Nanoparticles to Treat Alzheimer’s Disease

NORTH READING, Mass.--(BUSINESS WIRE)--Aphios announced today that it was awarded an NIH SBIR grant from the National Institute on Aging (NIA) to develop anti-CCR5 nanoparticles to treat Alzheimer’s ...
Business Insider

CytoDyn Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients in the United States

VANCOUVER, Washington, April 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 ...
Business Wire

CytoDyn Comments on Rosenbaum/Patterson Activist Group “Plan”

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple ...
Nasdaq

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer

VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential ...